You will find Grünenthal representatives from Business Development & Licensing usually at the following conferences:
BIO International Convention, April 22-25, 2013, Chicago/Il, USA
New chemical entities (NCE) in the areas of pain and inflammation as well as the formulation technology platform INTAC® are at the core of our presentation at BIO International Convention 2013. Our presence at BIO 2013 underscores the open approach for collaboration and discussing new opportunities.
Please visit us at our booth #5237 where a team of scientific as well as business development & licensing experts will be available for discussions.
Grünenthal Innovation encompasses the value generation from drug discovery to Proof-of-Concept in humans as well as the development of new drug-delivery technologies. Our business model builds on true partnership, especially in co-development and co-commercialization.
With regard to NCEs, the focus lies on selected therapeutic areas. The later stage pipeline continues to build on our leadership in developing new pain therapeutics, while in parallel a second pillar has been built: inflammation. This approach utilizes the highly interesting overlap and synergies between pain and inflammation, while at the same time establishes a unique position within the broad variety of inflammatory diseases.
Our innovative tamper-resistant technology, INTAC®, is featured in FDA-approved products, and we consider INTAC® to be the leading technology for abuse-deterrent and tamper-resistant opioid products. In addition to the already established ER TRF formulation, we have also developed an immediate-release TRF technology. Grünenthal is seeking to significantly expand the market in the US for INTAC®.
We are interested in partners from academia and biotech as well as pharma companies to collaborate and network. With our patient-centric innovation culture, we strive to address medical needs with the focus on pain and inflammatory disease pathways. This way, patients as well as partners benefit from innovative products.
More information on the formulation technology platform INTAC®: www.intac.grunenthal.com
- Bio2013 press release (pdf, 48.6 KB)